Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...

Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094.

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

The acquisition of HS-20094 enhances Regeneron’s portfolio of obesity and metabolic programs, which aim to improve the quality of weight loss and address long-term health comorbidities.

Regeneron Pharmaceuticals Inc. is adding to its obesity pipeline by in-licensing Hansoh Biomedical Co. Ltd.’s phase III dual ...

Regeneron Pharmaceuticals (REGN ... Hong Kong and Macau for a dual GLP-1/GIP receptor agonist, HS-20094, currently in Phase 3 testing.

On Monday, May 19, Regeneron Pharmaceuticals announced it had purchased most of 23andMe's assets for $256 million in cash at bankruptcy auction. The acquisition would cover "substantially all" of ...

Is Regeneron a good stock to buy now in light of a potential 23andMe acquisition? Here's a quick look at what it's paying for to find out. 23andMe's market cap peaked at $5.8 billion a few months ...

In a landmark move within the biotech industry, Regeneron Pharmaceuticals has announced its acquisition of 23andMe for $256 million. This deal, emerging from 23andMe's bankruptcy proceedings ...